SEC Company Response from Nautilus Biotechnology, Inc. (NAUT) (CIK 0001808805) (NAUT) — Aug 3, 2021
Nautilus Biotechnology, Inc. (NAUT) (CIK 0001808805)
Date: Aug. 3, 2021 · CIK: 0001808805 · Accession: 0001628280-21-015374
AI Filing Summary & Sentiment
File numbers found in text: 333-258100
Letter
Document
August 3, 2021
VIA EDGAR
U.S. Securities and Exchange Commission
Division of Corporation Finance
Office of Life Sciences
100 F Street, N.E.
Washington, D.C. 20549-3720
Attention: Irene Paik
Re: Nautilus Biotechnology, Inc.
Registration Statement on Form S-1
File No. 333-258100
Acceleration Request
Requested Date: August 6, 2021
Requested Time: 4:00 P.M. Eastern Time
Ladies and Gentlemen:
Pursuant to Rule 461 under the Securities Act of 1933, as amended, Nautilus Biotechnology, Inc. (the “Company”) hereby requests that the above-referenced Registration Statement on Form S-l (File No. 333-258100) (the “Registration Statement”) be declared effective at the “Requested Date” and “Requested Time” set forth above or at such later time as the Company or its counsel may orally request via telephone call to the staff of the Division of Corporation Finance of the Securities and Exchange Commission. Once the Registration Statement has been declared effective, please orally confirm that event with our counsel, Wilson Sonsini Goodrich & Rosati, P.C., by calling Zachary B. Myers at (858) 350-2350.
Sincerely,
NAUTILUS BIOTECHNOLOGY, INC.
Show Raw Text
CORRESP 1 filename1.htm Document August 3, 2021 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549-3720 Attention: Irene Paik Re: Nautilus Biotechnology, Inc. Registration Statement on Form S-1 File No. 333-258100 Acceleration Request Requested Date: August 6, 2021 Requested Time: 4:00 P.M. Eastern Time Ladies and Gentlemen: Pursuant to Rule 461 under the Securities Act of 1933, as amended, Nautilus Biotechnology, Inc. (the “Company”) hereby requests that the above-referenced Registration Statement on Form S-l (File No. 333-258100) (the “Registration Statement”) be declared effective at the “Requested Date” and “Requested Time” set forth above or at such later time as the Company or its counsel may orally request via telephone call to the staff of the Division of Corporation Finance of the Securities and Exchange Commission. Once the Registration Statement has been declared effective, please orally confirm that event with our counsel, Wilson Sonsini Goodrich & Rosati, P.C., by calling Zachary B. Myers at (858) 350-2350. Sincerely, NAUTILUS BIOTECHNOLOGY, INC. /s/ Sujal Patel Sujal Patel Chief Executive Officer cc: Anna Mowry Matthew Murphy Nautilus Biotechnology, Inc. Robert F. Kornegay Zachary B. Myers Wilson Sonsini Goodrich & Rosati, P.C.